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ABSTRACT
The most incessant skin malignancy is basal cell carcinoma (BCC), arising from cells of the basal layer of the epithelium or from 
the external root sheath of the hair follicle. BCC of the genital area is an aberrant subsistence. We are presenting one such rare case 
of BCC of the genital area which was not amenable to surgery because it was locally advanced disease if it was executed it may 
have result in highly mutilating surgery. Since the patient refused the main modality, the best available option for her was chemo-
radiotherapy for averting the post-surgical anatomical disfigurement of the private parts which may results in the psycho-social ordeal 
to the patient after loss of docility. The rationale of presenting this case is the rarity of BCC in the genital region and it should always 
kept in mind as a differential diagnosis by physicians, and biopsy from visible lesions is always recommended. Also, the majority of 
patients are treated with local treatment but in case of locally advanced or non-amenable lesions; induction chemotherapy followed 
by radiation/ chemoradiation therapy is an option and can be effective.
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Basal cell carcinomas (BCC) are common cutaneous malignancies characterstically on sun-exposed sites, with about 85% of reported cases occurring either on the head 
or neck [1]. Ultraviolet light exposure is an important etiologic 
factor in BCCs, and BCCs arising from non-sun- exposed areas 
are, therefore, very rare. In particular, the axilla, nipple, the genital 
and perianal areas are not likely to be exposed to ultraviolet light; 
thus, if BCC develops in these areas, other predisposing factors 
should be considered. Nevertheless, this carcinoma can arise, 
albeit rarely, in non-sun-exposed areas, such as the axilla, nipple, 
and the genital and perianal areas [2,3]. BCCs of the pubic area are 
exceedingly rare, i.e. about 0.05% of all BCCs [2]. We report the 
case of a BCC arising in the genital area which was treated with 
chemoradiotherapy at our institute and doing well for two years. 
CASE REPORT
A 67-years-old female presented with chief complaints of a 
lesion in the genital area for 2 years, it was insidious in onset and 
gradually progressive to the present size (as shown in Fig. 1) . 
Patient also complained of burning sensation and itching locally 
from the last 10 days, it was insidious in onset and gradually 
progressive and relived by taking medications from local hospital. 
There was no history of any radiation or chemical exposure.
On local examination, there was a reddish flat lesion of size 
2x1.5cm present over the posterior half of both labia minora 
and was non-tender (Fig. 1). No abnormality was found in per 
speculum, per-vaginum and per-rectal examination. There were 
no palpable lymph nodes in the bilateral inguinal or femoral 
region also no similar kind of lesion were present in other 
sites of the body. General physical examination was done and 
no abnormality was found.Systemic examination including the 
central nervous system, cardiovascular system, respiratory system 
all were within limits. Karnofsky performance status (KPS) was 
90. Vitals including pulse rate was 72 beats per minute, regular, 
good volume, blood pressure was 110/73 mm Hg taken in the 
right arm in sitting position.
Routine hematological and biochemistry were within 
normal limits. The biopsy was taken and a histopathological 
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Figure 1: A reddish flat lesion of size 2x1.5cm present over the 
posterior half of both labia minora (before starting the treatment).
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examination (HPE) was suggestive of basal cell carcinoma (Fig. 2). 
Complete metastatic workup was done. Magnetic resonance 
imaging (MRI) pelvis suggestive of short-T1 inversion recovery 
sequence (STIR) hyperintense lesion of size 2x1.5 cm seen involving 
bilateral labia minora (Left<Right) which was showing diffusion 
restriction on diffusion-weighted imaging (DWI) and post contrast-
enhancement on post-contrast image. This lesion lost fat planes with 
the urethra and vagina. Few lymph nodes were seen in the bilateral 
inguinal region, largest measuring 1.9x1.5 cm on the right side.
The patient was explained about the first treatment modality 
i.e. surgery, but the patient refused for surgery and agreed for 
chemotherapy and radiotherapy. So, she was given paclitaxel and 
cisplatin-based chemotherapy three cycles followed by chemo-
radiotherapy @ 50Gy/25#/5weeks with weekly cisplatin followed 
by a perineal boost of 14Gy/7#/1.5 weeks in frog-leg position. 
External beam radiation therapy was given by Theratron® 780e 
Cobalt-60 machines using two parallel and opposed fields till 
50Gy (Fig. 3a and 3b) followed by a perineal boost of 14Gy/7#/1.5 
weeks in frog-leg position (Fig. 3c). 
The patient had a complete response assessed by MRI pelvis 
after completion of treatment. The patient was kept on regular 
follow-up without any anatomical distortion and function, which 
was of paramount importance to the patient (Figure 4). During 
treatment, the patient had grade-II bowel, bladder toxicity, grade-I 
rectal toxicity, and grade-II skin and mucosal membrane toxicity, 
all were scored as per acute Radiation Therapy Oncology Group 
(RTOG) morbidity criteria. All acute toxicities were managed 
conservatively without affecting the treatment. During 2 years of 
follow-up, no late toxicity was noted.
DISCUSSION
The most important predisposing factor for BCC is chronic 
exposure to ultraviolet light (UVL), and more than 80% of 
BCCs are found in sun-exposed areas of the body, such as the 
face. Consequently, BCCs of the non-sun-exposed areas, such as 
nipple, axilla or the genital and perianal areas are extremely rare. 
Le Sueur et al[4] investigated 10,000 BCCs and only 15 axillary 
BCCs (0.05%) were identified. With regard to the BCCs of the 
nipple, less than 30 cases were reported in the world [5]. Gibson 
and Ahmed [2] reported 36 genital BCCs (0.2%) and 15 perianal 
BCCs (0.08%) out of a total of 18,943 investigated BCCs. Ten 
of the 36 genital BCCs occurred in the pubic area, representing 
0.05% of the cases studied. 
Given that these regions are usually not exposed to sun-light 
and well covered, other etiological factors should be considered 
when a patient presents with a BCC of the non-sun-exposed areas. 
These factors can be radiation therapy, alterations in immune 
surveillance, exposure to coal tar or arsenic, sexually transmitted 
diseases, burns, traumatic scars, and chronic skin irritation due 
to chronic dermatologic conditions, such as chronic dermatitis 
[6]. Korean authors [5,6,7] found no other etiologic factors in the 
cases of BCCs on the non-sun-exposed area reported till date, as 
was the case in our study.
In our case, the patient was not considered for surgery 
despite being the 1st preferred treatment of choice, keeping in 
mind the organ disfigurement which may have resulted after 
highly mutilating surgery for such anatomical sites. Also, BCC 
is radiosensitive as well as chemo-sensitive, so we exploit the 
benefit of both for the patient cure. As the patient declined 
surgery initially as well as after neoadjuvant chemotherapy 
and when we explored the literature, the role of chemotherapy 
was mentioned, although it was less [8,9,10] especially in 
non-amenable, advanced and metastatic disease.So chemo-
radiotherapy was chosen as treatment modality by the patient. 
The notion of administering neoadjuvant chemotherapy was to 
decrease the burden of disease as loco-regional lymph nodes were 
also present at the presentation. The patient was managed with 
radical treatment without any anatomical disfigurement.
The physicians might initially interpret these cancers as either 
inflammatory or infectious disease [11,12]. It is recommended 
that the physicians must consider the skin cancer as one of the 
differential diagnosis and biopsy of all suspect lesions should be 
performed, even if the BCC at these regions is dubious.
CONCLUSION
BCCs arising from the non-sun-exposed areas are although rare 
and may present for longer durations than those arising from 
other areas of the body. The majority of BCC patients are treated 
Figure 2: Figure showing High power image shows basaloid epithelial 
tumour cells arising from epidermis having mildly pleomorphic 
hyper-chromatic nuclei, scant cytoplasm and atypical mitosis. Tumour 
showed peripheral palisading, peritumoral clefting surrounded by 
myxoid stroma, features suggestive of basal cell carcinoma.
Figure 3: Portal showing (a) anterior field (Phase-I), (b) posterior 
field (Phase-I) and (c) frog leg position (Phase-II).
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by local treatments without the need for systemic chemotherapy. 
However, in non-amenable lesions, neo-adjuvant cisplatin-based 
chemotherapy following radiotherapy can be effectively used.
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Figure 4: Post-treatment picture of the patient with no disease.
